IMPORTANT NOTE. We strongly recommend that you consult your doctor for proper advice before using any medications, including vitamins, supplements, herbals and products for the skin.
Brand Name, Dosage Format and Strength
Kastair EZTab 5 mg TABLET
Therapeutic Category
Respiratory System
Sub Therapeutic
Antiasthmatic and COPD Preparations, Cough and Cold Preparations
Class
Corticosteroid, Anticholinergic, Beta2-Agonist, Leukotriene Inhibitor, Beta2-Agonist, Beta2-Agonist, Expectorant, Antiasthma-Beta2- Agonist, Mucolytic, Beta2-Agonist, Mucolytic, Antitussive, Nasal Decongestant, Analgesic-Antipyretic, Antitussive, Nasal Decongestant, Analgesic-Antipyretic, Nasal Decongestant, Antihistamine, Nasal Decongestant, Antihistamine, Analgesic-Antipyretic, Nasal Decongestant, Analgesic-Antipyretic, Alpha Adrenergic Agonist, Nasal Decongestant, Antihistamine, Analgesic-Antipyretic
Marketing Division
INTERACTION/S WITH OTHER MEDICAMENTS
The administration of montelukast with other drugs used in the prophylaxis and chronic treatment of asthma showed no apparent increase in adverse reactions.
Usual dosages of montelukast did not reveal clinically important effects on the pharmacokinetics of the following drugs: theophylline, warfarin, digoxin, oral contraceptives (ethinyl estradiol with norethindrone), prednisone, and prednisolone.
Concomitant use of montelukast with commonly prescribed drugs in clinical studies, e.g., thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants, showed no evidence of clinical adverse reactions.
Montelukast-treated patients with known aspirin sensitivity should continue to avoid aspirin and other NSAIDs. Although montelukast can improve airway function in asthmatics with aspirin sensitivity, the drug has not been shown to shorten the bronchoconstrictor response to aspirin or other NSAIDs in such patients. An anaphylactic reaction has been reported following exposure to a NSAID in at least one aspirin-sensitive individual receiving montelukast.
The AUC of montelukast decreased by approximately 40% with co-administration of phenobarbital. No dosage adjustment for montelukast is recommended. However, appropriate clinical monitoring should be initiated with concomitant administration of montelukast with potent cytochrome P450 enzyme inducers such as phenobarbital and rifampicin.